Medical School

Postgraduate research profiles


Julie Proudfoot

Phone: (+61 8) 9224 0392
Fax: (+61 8) 9224 0246

Start date

Mar 2010

Submission date

Aug 2016

Curriculum vitae

Julie Proudfoot CV
[doc, 140.88 kb]
Updated 26 Sep 2014

Julie Proudfoot

Julie Proudfoot profile photo


Identification of oxidation products of arachidonic acid within lipoproteins and their effects on lipoprotein properties and functions.


Atherosclerosis is a disease of the arteries, in which the walls of the blood vessels become thickened and hardened by plaques. The plaques are composed of cholesterol and other lipids, inflammatory cells, and calcium deposits.

High density lipoprotein (HDL) and low density lipoprotein (LDL) are found in the circulation. High levels of HDL are associated with a low risk for development of cardiovascular disease and are thought to play an important role in protection from this disease. LDL is proposed to be involved in the development of atherosclerosis where cells take up modified (oxidized) LDL producing fatty deposits and plaques which can eventually block arteries. HDL may prevent the modification of LDL and so reduce atherosclerosis.

We have shown that HDL and LDL are the major carriers of F2-isoprostanes, a class of compounds that represents oxidation of fats. F2-isoprostanes, along with other oxidation products, are formed in vivo via oxidation of arachidonic acid, the major polyunsaturated fatty acid in cell membranes. Although arachidonic acid oxidation products are known to be associated with lipids, their distribution within specific lipid classes in lipoprotein particles is unknown. This study will determine which species within the HDL and LDL particles contain arachidonic acid oxidation products and this in turn may give information about the source of these oxidized species.

The effect of F2-isoprostanes alone, or in the presence of lipoproteins, on macrophage cell spreading and migration will be determined. Macrophage spreading and migration is an important component in the development of atherosclerosis.

Why my research is important

The significance of this research will be its important contribution to knowledge regarding the atheroprotective effects of HDL and the proatherogenic properties of LDL. The distribution of F2-isoprostanes in HDL and LDL from healthy subjects may be compared to the distribution in subjects with cardiovascular disease and any differences may give insight into structural changes in lipoproteins. The influence of F2-isoprostanes and lipoproteins on macrophage spreading and migration, an important element of the development of atherosclerosis, may contribute to understanding of their roles in the progression of the disease.

These findings may lead to potential treatments for cardiovascular disease.


  • • 26 November 2009
  • Medical Research Foundation Royal Perth Hospital $15,000
  • Chief investigator on the grant “Distribution of F2-Isoprostanes in Plasma Lipoproteins.”
  • • 30 November 2009
  • National Heart Foundation $64,500
  • A chief investigator on the grant “The role of F2-isoprostanes in HDL.”
  • • 26 April 2010
  • Faculty of Medicine, Dentistry and Health Sciences Small Equipment Grant $27,210

Mouse macrophages